April 18, 2021
Article
Pathologic antibodies to platelet factor 4 in patients who developed clots after the AstraZeneca vaccine indicates treatment include non-heparin anticoagulant.
April 16, 2021
April 15, 2021
The 2 shot mRNA vaccine has a high efficacy against COVID-19, but long term data for its protection is not there yet, and emerging variants may present a challenge.
Increased facility-level vaccine coverage amongst residents and staff was associated with lower cases in the latter population.
April 14, 2021
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met today to discuss the blood clots’ issue and offered guidance on heparin usage in these cases.
Video
An interventional cardiologist discusses the observed cases of cerebral venous thrombosis in women administered the Johnson & Johnson COVID-19 vaccine.
April 13, 2021
Carlos del Rio, MD, discusses the United States' pandemic situation in assessing the blood clot events observed in 6 Johnson & Johnson vaccine recipients.
Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.
In a press conference this morning, leadership of the FDA and CDC discussed why they made the decision on this vaccine and announced an ACIP meeting will be held tomorrow to review the data from the adverse events.
The federal agencies will advise states withhold administration of the Johnson & Johnson one-shot product while investigating risk of a rare blood clot disorder.
